| Evidence-based management of immune thrombocytopenia: ASH guideline update |
18 |
| Gene therapy for hemophilia |
13 |
| Clinical and laboratory diagnosis of TTP: an integrated approach |
12 |
| New drugs for acute myeloid leukemia inspired by genomics and when to use them |
11 |
| Drug-associated thrombocytopenia |
10 |
| Autoimmune hemolytic anemia |
10 |
| Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura |
9 |
| Long-term complications in adolescent and young adult leukemia survivors |
8 |
| Genetics and prognosis of ALL in children vs adults |
8 |
| Are CAR T cells better than antibody or HCT therapy in B-ALL? |
8 |
| Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria |
7 |
| Measuring success: utility of biomarkers in sickle cell disease clinical trials and care |
7 |
| How do we diagnose immune thrombocytopenia in 2018? |
7 |
| Meeting the needs of CML patients in resource-poor countries |
7 |
| Antibody-based therapies in patients with acute lymphoblastic leukemia |
6 |
| Inflammatory bone marrow microenvironment |
6 |
| From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms |
6 |
| JMML genomics and decisions |
6 |
| Inherited hemolytic anemia: a possessive beginner's guide |
6 |
| Management of thrombosis in children and neonates: practical use of anticoagulants in children |
6 |
| The growing landscape of FLT3 inhibition in AML |
5 |
| Single-agent and combination biologics in acute myeloid leukemia |
5 |
| MRD evaluation of AML in clinical practice: are we there yet? |
5 |
| Pediatric ITP: is it different from adult ITP? |
5 |
| Alternative donor transplants for severe aplastic anemia |
5 |
| TTP: long-term outcomes following recovery |
4 |
| Treatment of primary immunodeficiency with allogeneic transplant and gene therapy |
4 |
| We do still transplant CML, don't we? |
4 |
| Update from the clinic: what's new in the diagnosis of cancer-associated thrombosis? |
4 |
| Adolescent angst: enrollment on clinical trials |
4 |
| The MDS genomics-prognosis symbiosis |
4 |
| A brief, but comprehensive, guide to clonal evolution in aplastic anemia |
4 |
| New insights into the pathophysiology and development of novel therapies for sickle cell disease |
4 |
| Preventing and managing catastrophic bleeding during extracorporeal circulation |
4 |
| Genetic predisposition to MDS: diagnosis and management |
3 |
| Hypereosinophilic syndrome: approach to treatment in the era of precision medicine |
3 |
| Ethical conundrums in pediatric genomics |
3 |
| Selecting Frontline Therapy for CLL in 2018 |
3 |
| Biology-driven developments in the therapy of acute graft-versus-host disease |
3 |
| Richter transformation in the era of novel agents |
3 |
| Integrating patient-centered factors in the risk assessment of MDS |
3 |
| New diagnostic tools for delineating iron status |
3 |
| Iron overload in transfusion-dependent patients |
3 |
| Myeloma: next generation immunotherapy |
3 |
| Mechanisms of and approaches to overcoming resistance to immunotherapy |
3 |
| Cytotoxic therapy in acute myeloid leukemia: not quite dead yet |
3 |
| JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy |
3 |
| Managing myelofibrosis (MF) that blasts through: advancements in the treatment of relapsed/refractory and blast-phase MF |
3 |
| The new tool KIT in advanced systemic mastocytosis |
3 |
| Challenges and implications of genomics for T-cell lymphomas |
3 |
